Insider Transactions in Q1 2024 at Immunity Bio, Inc. (IBRX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 05
2024
|
Richard Adcock CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
43,165
-15.08%
|
$172,660
$4.04 P/Share
|
|
Feb 05
2024
|
Richard Adcock CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
83,334
+22.54%
|
-
|
|
Jan 31
2024
|
Barry J. Simon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
22,094
-0.7%
|
$66,282
$3.36 P/Share
|
|
Jan 31
2024
|
Barry J. Simon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
57,200
+1.79%
|
-
|
|
Jan 31
2024
|
Regan J Lauer Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,470
-12.49%
|
$40,410
$3.36 P/Share
|
|
Jan 31
2024
|
Regan J Lauer Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,872
+23.37%
|
-
|
|
Jan 31
2024
|
David C. Sachs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
26,835
-12.62%
|
$80,505
$3.36 P/Share
|
|
Jan 31
2024
|
David C. Sachs Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
70,745
+24.96%
|
-
|